SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes

被引：0
|
作者：
Gajos, Grzegorz [1 ,2 ]
机构：
[1] Jagiellonian Univ Med Coll, Inst Cardiol, Dept Coronary Artery Dis & Heart Failure, Krakow, Poland
[2] St John Paul II Hosp, Krakow, Poland
来源：
CARDIOLOGY JOURNAL | 2024年 / 31卷 / 05期
关键词：
D O I：
10.5603/cj.102158
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：782 / 783
页数：2
相关论文
共 50 条
  • [41] Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
    Pagidipati, Neha J.
    Zheng, Yinggan
    Green, Jennifer B.
    McGuire, Darren K.
    Mentz, Robert J.
    Shah, Svati
    Aschner, Pablo
    Delibasi, Tuncay
    Rodbard, Helena W.
    Westerhout, Cynthia M.
    Holman, Rury R.
    Peterson, Eric D.
    AMERICAN HEART JOURNAL, 2020, 219 : 47 - 57
  • [42] A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes
    Carney, Ellen F.
    NATURE REVIEWS NEPHROLOGY, 2024, 20 (08) : 493 - 493
  • [43] Obesity and novel cardiovascular markers in a population without diabetes and cardiovascular disease in China
    Zeng, Qiang
    Dong, Sheng-Yong
    Wang, Man-Liu
    Li, Jin-Ming
    Ren, Chong-Lei
    Gao, Chang-Qing
    PREVENTIVE MEDICINE, 2016, 91 : 62 - 69
  • [44] Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
    Lingvay, Ildiko
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lincoff, A. Michael
    Marso, Steven P.
    Fries, Tea Monk
    Plutzky, Jorge
    Ryan, Donna H.
    OBESITY, 2023, 31 (01) : 111 - 122
  • [45] Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes
    Singh, Sahib
    Garg, Aakash
    Tantry, Udaya S.
    Bliden, Kevin
    Gurbel, Paul A.
    Gulati, Martha
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 218 : 24 - 31
  • [46] GLP-1 Receptor Agonists Improve Cardiovascular Outcomes in Patients With Celiac Disease and Obesity
    Nieto, Luis
    Narvaez, Sharon
    Shepherd, Katherine
    Adeniran, Olanrewaju
    Vega, Kenneth
    Haggerty, Treah
    Davisson, Laura
    OBESITY, 2024, 32 : 87 - 88
  • [47] Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study
    Ghusn, Wissam
    Anazco, Diego
    Fansa, Sima
    Tama, Elif
    De La Rosa, Alan
    Nicolalde, Bryan
    Cifuentes, Lizeth
    Sacoto, Daniel
    Campos, Alejandro
    Feris, Fauzi
    Gala, Khushboo
    Calderon, Gerardo
    Hashem, Anas
    Hurtado, Maria Daniela
    Acosta, Andres
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1234 - S1235
  • [48] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes reply
    Husain, Mansoor
    Donsmark, Morten
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2076 - 2077
  • [49] Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
    Mahaffey, Kenneth W.
    Tuttle, Katherine R.
    Arici, Mustafa
    Baeres, Florian M. M.
    Bakris, George
    Charytan, David M.
    Cherney, David Z., I
    Chernin, Gil
    Correa-Rotter, Ricardo
    Gumprecht, Janusz
    Idorn, Thomas
    Pugliese, Giuseppe
    Rasmussen, Ida Kirstine Bull
    Rasmussen, Soren
    Rossing, Peter
    Sokareva, Ekaterina
    Mann, Johannes F. E.
    Perkovic, Vlado
    Pratley, Richard
    EUROPEAN HEART JOURNAL, 2024,
  • [50] Diabetes, obesity and cardiovascular disease
    Friday, KE
    HORMONE REPLACEMENT THERAPY AND CARDIOVASCULAR DISEASE: THE CURRENT STATUS OF RESEARCH AND PRACTICE, 2001, : 37 - 45
12345